INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022PRNewsWire • 05/27/22
Inovio lets go of CEO, to stop work on COVID-19 vaccine and instead focus on boosterMarket Watch • 05/11/22
Inovio Pharmaceuticals, Inc. (INO) on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/10/22
INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive OfficerPRNewsWire • 05/10/22
Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy PlatformPRNewsWire • 03/24/22
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Oppenheimer's 32nd Annual Healthcare Conference (Transcript)Seeking Alpha • 03/15/22
Lab Study Shows Inovio's COVID-19 Vaccine Candidate Weaker Against Omicron VariantBenzinga • 03/02/22